Neuland Laboratories Ltd
NSE:NEULANDLAB

Watchlist Manager
Neuland Laboratories Ltd Logo
Neuland Laboratories Ltd
NSE:NEULANDLAB
Watchlist
Price: 13 838.75 INR 0.26% Market Closed
Market Cap: 177.6B INR
Have any thoughts about
Neuland Laboratories Ltd?
Write Note

Neuland Laboratories Ltd
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Neuland Laboratories Ltd
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Neuland Laboratories Ltd
NSE:NEULANDLAB
Current Portion of Long-Term Debt
â‚ą476.8m
CAGR 3-Years
-26%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Current Portion of Long-Term Debt
â‚ą41.2B
CAGR 3-Years
256%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Current Portion of Long-Term Debt
â‚ą2.4B
CAGR 3-Years
48%
CAGR 5-Years
N/A
CAGR 10-Years
-17%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Current Portion of Long-Term Debt
â‚ą22B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Current Portion of Long-Term Debt
â‚ą16.5B
CAGR 3-Years
-6%
CAGR 5-Years
-1%
CAGR 10-Years
N/A
M
Mankind Pharma Ltd
NSE:MANKIND
Current Portion of Long-Term Debt
â‚ą231.2m
CAGR 3-Years
5%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Neuland Laboratories Ltd
Glance View

Market Cap
178.5B INR
Industry
Pharmaceuticals

Neuland Laboratories Ltd., with its roots firmly planted in the bustling pharmaceutical sector of India, presents a captivating narrative of innovation and strategic growth. Founded in 1984 by Dr. D.R. Rao, the venture initially embarked on its journey by manufacturing Active Pharmaceutical Ingredients (APIs), essential components that power numerous medical treatments. Situated in Hyderabad, the company swiftly carved out a niche by focusing on complex and high-value APIs, earning a reputation for quality and reliability. This strategy enabled Neuland to establish long-standing relationships with prominent generic pharmaceutical companies across the globe. As the world of pharmaceuticals evolved, so did Neuland's approach to business. The company shifted gears to not just produce APIs but also ventured into Contract Research and Manufacturing Services (CRAMS), capitalizing on the growing demand for customized pharmaceutical development and production services. This not only diversified their revenue streams but also aligned them with the needs of various pharmaceutical innovators striving for precision and customization in their drug formulations. With a commitment to regulatory compliance and a robust infrastructural foundation, Neuland Laboratories continues to bolster its position in the market, marrying its time-honored expertise in chemistry with cutting-edge technological advancements to drive profitability and sustain its international footprint.

NEULANDLAB Intrinsic Value
5 807.51 INR
Overvaluation 58%
Intrinsic Value
Price

See Also

What is Neuland Laboratories Ltd's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
476.8m INR

Based on the financial report for Sep 30, 2024, Neuland Laboratories Ltd's Current Portion of Long-Term Debt amounts to 476.8m INR.

What is Neuland Laboratories Ltd's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 3Y
-26%

Over the last year, the Current Portion of Long-Term Debt growth was 19%. The average annual Current Portion of Long-Term Debt growth rates for Neuland Laboratories Ltd have been -26% over the past three years .

Back to Top